14 August 2024 in Toxicological Sciences
Evaluating the mutagenic properties of chemicals is crucial for understanding their potential cancer risks. Recent Illumina-based error-corrected sequencing techniques have enabled the direct detection of mutations induced de novo by mutagens. However, as the Illumina platform lacks intrinsic error-correction capabilities, complex library preparations and bioinformatic processes are necessary to identify these rare mutations. In this study, we evaluated whether long-read PacBio-based HiFi sequencing (HiFi seq), which has integrated error-correction, can detect de novo mutations induced by mutagens in C57BL/6 mouse tissues. Using HiFi seq, dose-dependent increases in mutation frequencies were found in tissues from mice exposed to 7,12-dimethylbenz[a]anthracene, procarbazine, and N-propyl-N-nitrosourea. Furthermore, the mutational signatures derived from these exposures were consistent with those previously reported for these mutagens. This study demonstrates that HiFi seq can complement established mutation detection assays to facilitate the identification of hazardous compounds.
22 August 2025 in Journal of Environmental Science and Health, Part C
Accurately evaluating chemical risk may benefit from the development of human-relevant models capable of capturing the effects of treatments that closely mimic real-world environmental and pharmaceutical exposures. Building on our previous work (Seo et al. Arch Toxicol 98:1919-1935),1 where cytotoxicity compromised mutation detection following short-term treatments, this study investigated mutation accumulation in both 2D and 3D HepaRG cultures following 7- and 14-day exposures with relatively non-cytotoxic N-nitrosodimethylamine (NDMA) concentrations. A multi-endpoint approach was employed to assess NDMA-induced DNA damage, micronucleus formation, and mutagenesis. Seven-day NDMA treatments were not cytotoxic but produced concentration-dependent increases in DNA damage and mutations. After 14 days of exposure, the highest NDMA concentrations produced no more than 30% cytotoxicity, and induced greater mutation frequencies compared to the 7-day exposures. Overall, the mutation frequencies induced by NDMA exhibited concentration- and treatment-duration-dependent relationships in both 2D and 3D HepaRG cultures, with notably higher mutation frequencies in 3D spheroids than in 2D cultures. Quantitative analysis by benchmark concentration (BMC) modeling demonstrated lower BMC values in 3D spheroids compared to their 2D counterparts. The predominant mutation in NDMA-treated cultures was T→C transition. These findings indicate the value of extended exposure periods for conducting in vitro genotoxicity testing in HepaRG cells.
8 March 2026 in NAM Journal
The Enhanced Ames Test (EAT) is currently recommended by regulatory authorities for evaluating the mutagenicity of N-nitrosamine drug impurities, including nitrosamine drug substance-related impurities (NDSRIs). In previous studies, we developed protocols to evaluate the genotoxicity and mutagenicity of NDSRIs in both two-dimensional (2D) and three-dimensional (3D) HepaRG cell cultures as a follow-up to verify EAT findings. In this study, we investigated the genotoxicity and mutagenicity of six EAT-positive NDSRIs, N-nitroso-desmethyl-diphenhydramine, N-nitroso-duloxetine, N-nitroso-lorcaserin, N-nitroso-nortriptyline, N-nitroso-propranolol, and N-nitroso-sertraline, in 3D HepaRG spheroids using a 14-day treatment protocol. Genotoxicity was evaluated using the CometChip DNA damage assay and the micronucleus (MN) assay, while mutagenesis was measured with an error-corrected sequencing (ECS) method, High-Fidelity sequencing (HiFi-seq). The six EAT-positive NDSRIs induced time- and concentration-dependent cytotoxicity in HepaRG spheroids. All except N-nitroso-lorcaserin caused DNA damage, while only N-nitroso-propranolol induced MN formation at acceptable levels of cytotoxicity. Notably, all six EAT-positive NDSRIs significantly increased mutation frequency in HepaRG spheroids, each exhibiting distinct mutational spectra. Quantitative analysis revealed varying levels of DNA damage and mutagenic potency among the six NDSRIs and two previously reported NDSRIs (N-nitroso-varenicline and N-nitroso-fluoxetine). These findings represent an important first step towards supporting the use of 3D HepaRG spheroids as a human-relevant in vitro new approach methodology (NAM) for mutagenicity assessment as a follow-up to the EAT. The results also provide evidence for genotoxic potency ranking of NDSRIs and offer mechanistic insights through mutational spectrum analysis.